GlassScriptPrepare for your visit
Ali Ashrafzadeh
Rheumatology · Los Angeles, CA · NPI 1962447060
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$7,783.49
in general payments reported to CMS, 2019-2025 · $37.24 in 2025
The $37.24 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Who reported paying
General payments only, top 6 by amount.
- Boehringer Ingelheim International Gmbh $6,165.38
- Eli Lilly and Company $771.24
- Amgen INC. $246.74
- Abbvie INC. $246.39
- Genzyme Corporation $103.52
- Mallinckrodt Enterprises LLC $80.37
Drugs and devices associated with these payments
Tremfya Ubrelvy Skyrizi
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Ali Ashrafzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/88567/ali-ashrafzadeh